EUCTR2010-018273-38-FR进行中（未招募）1 期
A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography (qEEG) and Event-Related Potentials (ERP) in Patients with Mild-to-Moderate Alzheimer's Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of written informed consent from patient and caregiver before initiation of any study related procedures. Patients who are deemed incapable of providing informed consent may be enrolled if written informed consent has been obtained from the patient’s Legally Authorized Representative in accordance with local regulation
- •2. The patient and caregiver should understand, speak and read local language
- •3. The patient and the caregiver should be able to understand and comply with the requirements of the study, as judged by the investigator
- •4. Males and non-fertile females, 55-85 years, inclusive at day of enrollment
- •5. Clinical diagnosis of probable AD according to the NINCDS-ADRDA criteria
- •6. History of progressive worsening of memory and other cognitive functions for at least 12 months
- •7. A Hachinski Ischaemic Score =4, during enrollment (Visit 1).
- •8. CT or MRI scan within the past 6 months (performed after onset of dementia) consistent with the diagnosis of AD. If the CT/MRI test is older than 6 months, the patient will need to renew the CT/MRI to confirm the diagnosis
- •9. MMSE score 18-24
- •10. A body mass index (BMI=weight/height2) of 18-30 kg/m2 as calculated by the investigator at enrollment
- •11. Clcrea =60 mL/min estimated according to the formula by Cockcroft and Gault with S-Cr determined by Jaffe’s method (or if the enzymatic method is used, the S-Cr value used for calculating CLcrea should reflect the expected value as if the Jaffé method was used).
- •12. Male patients should be willing to use barrier contraception, ie, condoms, even if their partners are post-menopausal, surgically sterile or are using accepted contraceptive methods, from the first day of dosing until 3 months after the last dose of investigational product (IP)
- •13. Recordable P300
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Significant neurological disease or dementia other than AD, eg, mixed dementia, frontotemporal dementia and Parkinson’s disease, that may affect cognition or ability to complete the study
- •2. Possible, probable or definite vascular dementia in accordance with NINDS-AIREN criteria
- •3. Current major depressive disorder or other major psychiatric disorders according to the DSM-IV criteria
- •4. Current significant or unstable disease/disorder that, in the judgment of the investigator, is likely to deteriorate or affect the patient’s safety, influence cognitive assessments or affect ability to complete the study.
- •5. History of any malignant disease within the past 5 years with the exception of minor superficial skin diseases (ie, basal cell carcinoma and squamous cell carcinoma)
- •6. Poorly controlled diabetes mellitus, as judged by the investigator, or diabetes mellitus patient requiring any dose of insulin within the last 6 months. Insulin treated patients should be excluded since fluctuation in blood sugar may affect the cognitive assessments
- •7. Having known or suspected systemic serious infection (eg, HBV, HCV, HIV, tuberculosis) as judged by the investigator
- •8. Poorly controlled hypertension as judged by investigator
- •9. Myocardial infarction or acute coronary syndrome within the last year
- •10. Clinically significant ECG abnormalities as judged by the investigator based on assessment by a centrally located experienced cardiologist interpreting the ECG
- •11. Prolonged QTcF>450 msec or shortened QTcF<350 msec or family history of long QT syndrome
- •12. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results as judged by the investigator
- •13. Having a suspected or not sufficiently substituted hypothyreosis, vitamin B12 or folic acid deficiency
- •14. Clinically significant abnormal findings in physical examination or vital signs that may affect the ability of the patient to complete study procedures, patient safety or data interpretation, as judged by the investigator
- •15. Having one or more of the following histamine associated criteria
- •-History of severe allergy/hypersensitivity reactions including severe food allergy as judged by the investigator
- •-History of Quincke oedema, angiooedema or urticaria pigmentosa, or history of repeated episodes of urticaria, regardless causative agent
- •-History or present symptoms or signs of asthma of any severity as judged by the investigator
- •-History of hypersensitivity to drugs of a similar class to AZD1446 as judged by the Investigator
- •-Eosinophilia (ie, > upper limit of normal local lab reference limit, at enrollment)
- •16. Impaired vision and hearing making cognitive testing difficult as judged by the investigator
- •17. Women who are of childbearing potential, ie, not surgically sterile or post-menopausal for at least 12 months
- •18. Male patients planning to father a child or donate sperm during the study period and within 3 months after last intake of study drug
研究者
相似试验
招募中
1 期
Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsible for epithelial growth (EGF-R) that progressed after the treatment with other drugs.Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI TreatmentMedDRA version: 21.0Level: PTClassification code: 10025125Term: Lung squamous cell carcinoma stage IV Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10025124Term: Lung squamous cell carcinoma stage III Class: 100000004864CTIS2023-504434-22-00Summit Therapeutics Sub Inc.481
进行中（未招募）
1 期
Study Evaluating ALX-0061 Administered Subcutaneously in Patients with Systemic Lupus ErythematosusModerate to Severe Active Systemic Lupus ErythematosusMedDRA version: 20.0Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000017968EUCTR2015-000372-95-CZAblynx N.V.300
进行中（未招募）
1 期
Study Evaluating ALX-0061 Administered Subcutaneously in Patients with Systemic Lupus ErythematosusModerate to Severe Active Systemic Lupus ErythematosusMedDRA version: 18.0Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2015-000372-95-ESAblynx N.V.300
进行中（未招募）
1 期
Study Evaluating ALX-0061 Administered Subcutaneously in Patients with Systemic Lupus ErythematosusModerate to Severe Active Systemic Lupus ErythematosusMedDRA version: 19.0Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2015-000372-95-DEAblynx N.V.300
进行中（未招募）
1 期
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antogonist, GW679769, when administered as 50 mg, 100 mg and 150 mg oral tablets in combination with Ondansetron Hydrochloride and Dexamethasone for the PRevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Moderately Emetogenic Chemotherapy.Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)EUCTR2004-001020-20-ESGlaxoSmithKline Group of Companies